LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
Authors
Keywords
MET inhibitor, LY2801653, MST1R, MKNK, ROS1
Journal
INVESTIGATIONAL NEW DRUGS
Volume 31, Issue 4, Pages 833-844
Publisher
Springer Nature
Online
2012-12-28
DOI
10.1007/s10637-012-9912-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
- (2012) Ted Underiner et al. Anti-Cancer Agents in Medicinal Chemistry
- Phosphoproteomics Identifies Driver Tyrosine Kinases in Sarcoma Cell Lines and Tumors
- (2012) Y. Bai et al. CANCER RESEARCH
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer
- (2011) Chen-Yun Yeh et al. BMC CANCER
- Ron Kinase Transphosphorylation Sustains MET Oncogene Addiction
- (2011) S. Benvenuti et al. CANCER RESEARCH
- Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer
- (2011) Tadaaki Yamada et al. Journal of Thoracic Oncology
- Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression and Induces Vascular Normalization
- (2011) T. Meier et al. MOLECULAR CANCER THERAPEUTICS
- Targeting Axl and Mer Kinases in Cancer
- (2011) A. Verma et al. MOLECULAR CANCER THERAPEUTICS
- Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
- (2011) Ting-Lei Gu et al. PLoS One
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- (2011) Peter S. Hammerman et al. Cancer Discovery
- The role of the c-Met pathway in lung cancer and the potential for targeted therapy
- (2011) Martin Sattler et al. Therapeutic Advances in Medical Oncology
- Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
- (2010) Christian C. Lee et al. BIOCHEMICAL JOURNAL
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development
- (2010) T. Ueda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now